Development of a human antibody fragment directed against the alpha folate receptor as a promising molecule for targeted application

References

• Ab O, Whiteman KR, Bartle LM, et al. (2015). IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Mol Cancer Ther 14:1605–13.
   PubMed Web of Science ®Google Scholar
• Adams GP, Schier R, Marshall K, et al. (1998). Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58:485–90.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Iwata T, Leung HY. (2012). Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta 1823:850–60.
   PubMed Web of Science ®Google Scholar
• Allard J, Risinger J, Morrison C, et al. (2007). Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol 107:52–7.
   PubMed Web of Science ®Google Scholar
• Arbabi Ghahroudi M, Desmyter A, Wyns L, et al. (1997). Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414:521–6.
   PubMed Web of Science ®Google Scholar
• Azzazy HM, Highsmith WE. Jr. (2002). Phage display technology: clinical applications and recent innovations. Clin Biochem 35:425–45.
   PubMed Web of Science ®Google Scholar
• Bannas P, Lenz A, Kunick V, et al. (2015). Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection. Contrast Media Mol Imaging 10:367–78.
   PubMed Web of Science ®Google Scholar
• Baral TN, Chao SY, Li S, et al. (2012). Crystal structure of a human single domain antibody dimer formed through V(H)-V(H) non-covalent interactions. PLoS One 7:e30149.
   PubMed Web of Science ®Google Scholar
• Barkhordarian H, Emadi S, Schulz P, et al. (2006). Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng Design Select PEDS 19:497–502.
   PubMed Web of Science ®Google Scholar
• Bates A, David PC. vs. Goliath: (2019 Apr 9). The structure, function, and clinical prospects of antibody fragments. Antibodies. 8:28.
   Web of Science ®Google Scholar
• Bayat AA, Yeganeh O, Ghods R, et al. (2013). Production and characterization of a murine monoclonal antibody against human ferritin. Avicenna J Med Biotechnol 5:212–219.
   PubMedGoogle Scholar
• Bazan J, Całkosiński I, Gamian A. (2012). Phage display–a powerful technique for immunotherapy: 1. Introduction and Potential of Therapeutic Applications. Human Vaccines & Immunotherapeutics 8:1817–28.
   PubMed Web of Science ®Google Scholar
• Beatty JD, Beatty BG, Vlahos WG. (1987). Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 100:173–9.
   PubMed Web of Science ®Google Scholar
• Brown Jones M, Neuper C, Clayton A, et al. (2008). Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas. Int J Cancer 123:1699–703.
   PubMed Web of Science ®Google Scholar
• Carmen S, Jermutus L. (2002). Concepts in antibody phage display. Brief Funct Genomic Proteomic 1:189–203.
   PubMedGoogle Scholar
• Davies J, Riechmann L. (1996). Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng 9:531–7.
   PubMedGoogle Scholar
• Fernández M, Javaid F, Chudasama V. (2018). Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci 9:790–810.
   PubMed Web of Science ®Google Scholar
• Furler RL, Nixon DF, Brantner CA, et al. (2018). TGF-β Sustains Tumor Progression through Biochemical and Mechanical Signal Transduction. Cancers 10:199.
   PubMed Web of Science ®Google Scholar
• Goldman ID, Chattopadhyay S, Zhao R, et al. (2010). The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs. Curr Opin Investigational Drugs. 11:1409–23.
   PubMedGoogle Scholar
• Hairul Bahara NH, Chin ST, Choong YS, et al. (2016). Construction of a semisynthetic human VH single-domain antibody library and selection of domain antibodies against α-crystalline of mycobacterium tuberculosis. J Biomol Screen 21:35–43.
   PubMedGoogle Scholar
• Harmsen MM, De Haard HJ. (2007). Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77:13–22.
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Keeney GL, Lingle WL, et al. (2007). Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121:938–42.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. (2014). Human Epidermal Growth Factor Receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Inter. 2014:852748.
   PubMedGoogle Scholar
• Iwakiri S, Sonobe M, Nagai S, et al. (2008). Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol 15:889–99.
   PubMed Web of Science ®Google Scholar
• Jäger D, Jäger E, Knuth A. (2001). Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 54:669–74.
   PubMed Web of Science ®Google Scholar
• Kalli KR, Oberg AL, Keeney GL, et al. (2008). Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108:619–26.
   PubMed Web of Science ®Google Scholar
• Keyaerts M, Xavier C, Heemskerk J, et al. (2016). Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med 57:27–33.
   PubMed Web of Science ®Google Scholar
• Konner JA, Bell-McGuinn KM, Sabbatini P, et al. (2010). Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16:5288–95.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Scheurich P, Pfizenmaier K. (2009). Antagonists of TNF action: clinical experience and new developments. Expert Opin Drug Discov 4:279–92.
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Ye Y, et al. (2006). Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66:3214–21.
   PubMed Web of Science ®Google Scholar
• Lambert JM. (2013). Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 76:248–62.
   PubMed Web of Science ®Google Scholar
• Lee CM, Iorno N, Sierro F, et al. (2007). Selection of human antibody fragments by phage display. Nat Protoc 2:3001–8.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Lee J-Y, Park M-H, et al. (2017). Monoclonal antibody against G Glycoprotein increases respiratory syncytial virus clearance in vivo and prevents vaccine-enhanced diseases. PLoS One 12:e0169139–e0169139.
   PubMed Web of Science ®Google Scholar
• Li B, Fouts AE, Stengel K, et al. (2014). In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation. MAbs 6:437–45.
   PubMed Web of Science ®Google Scholar
• Lim CC, Woo PCY, Lim TS. (2019). Development of a Phage display panning strategy utilizing crude antigens: isolation of MERS-CoV nucleoprotein human antibodies. Sci Rep 9:6088.
   PubMed Web of Science ®Google Scholar
• Liu H, May K. (2012). Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 4:17–23.
   PubMed Web of Science ®Google Scholar
• Lobstein J, Emrich CA, Jeans C, et al. (2012). SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. Microb Cell Fact 11:56.
   PubMed Web of Science ®Google Scholar
• Michael N, Accavitti MA, Masteller E, et al. (1998). The antigen-binding characteristics of mAbs derived from in vivo priming of avian B cells. Proc Natl Acad Sci U S A 95:1166–1171.
   PubMed Web of Science ®Google Scholar
• Moore KN, Martin LP, O'Malley DM, et al. (2018). A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncology (London, England 14:123–36.
   PubMed Web of Science ®Google Scholar
• Nagai T, Furusho Y, Li H, et al. (2015). Production of a high-affinity monoclonal antibody reactive with folate receptors alpha and beta. Monoclon Antib Immunodiagn Immunother 34:181–90.
   PubMedGoogle Scholar
• Ohlin M, Sundqvist VA, Gilljam G, et al. (1991). Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus. Clin Exp Immunol 84:508–514.
   PubMed Web of Science ®Google Scholar
• Patel NR, Piroyan A, Nack AH, et al. (2016). Design, synthesis, and characterization of folate-targeted platinum-loaded theranostic nanoemulsions for therapy and imaging of ovarian cancer. Mol Pharm 13:1996–2009.
   PubMed Web of Science ®Google Scholar
• Ponte JF, Ab O, Lanieri L, et al. (2016). Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia (New York, NY) 18:775–84.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Fernandez S, Murillo M, Villalba A, et al. (2019). Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential. Front. Immunol 10:2811.
   PubMed Web of Science ®Google Scholar
• Rudnick SI, Lou J, Shaller CC, et al. (2011). Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 71:2250–2259.
   PubMed Web of Science ®Google Scholar
• Sato S, Itamochi H. (2016). Profile of farletuzumab and its potential in the treatment of solid tumors. Onco Targets Ther 9:1181–8.
   PubMed Web of Science ®Google Scholar
• Shen J, Hu Y, Putt KS, et al. (2018). Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget 12:4485–95.
   Google Scholar
• Shen J, Putt KS, Visscher DW, et al. (2015). Assessment of folate receptor-β expression in human neoplastic tissues. Oncotarget 6:14700–9.
   PubMedGoogle Scholar
• Shi H, Liu L, Wang Z. (2013). Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett 328:191–7.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2017). Cancer statistics, 2017. CA Cancer J Clin 67:7–30.
   PubMed Web of Science ®Google Scholar
• Sirimangkalakitti N, Chamni S, Charupant K, et al. (2016). Chemistry of Renieramycins. 15. Synthesis of 22-O-Ester Derivatives of Jorunnamycin A and Their Cytotoxicity against Non-Small-Cell Lung Cancer Cells. J Nat Prod 79:2089–93.
   PubMed Web of Science ®Google Scholar
• Sokolowska-Wedzina A, Chodaczek G, Chudzian J, et al. (2017). High-affinity internalizing human scFv-Fc antibody for targeting FGFR1-overexpressing lung cancer. Mol Cancer Res 15:1040–50.
   PubMed Web of Science ®Google Scholar
• Srinivasarao M, Galliford CV, Low PS. (2015). Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov 14:203–19.
   PubMed Web of Science ®Google Scholar
• Syrkina MS, Vassetzky YS, Rubtsov MA. (2019). MUC1 Story: Great Expectations, Disappointments and the Renaissance. Curr Med Chem 26:554–63.
   PubMed Web of Science ®Google Scholar
• Tamura T, Kurishima K, Nakazawa K, et al. (2015). Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 3:217–21.
   PubMed Web of Science ®Google Scholar
• Teng Y, Young JL, Edwards B, et al. (2020). Diverse human V(H) antibody fragments with bio-therapeutic properties from the Crescendo Mouse. New Biotechnol 55:65–76.
   PubMed Web of Science ®Google Scholar
• Thundimadathil J. (2012). Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012:967347.
   PubMedGoogle Scholar
• Toffoli G, Russo A, Gallo A, et al. (1998). Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 79:121–6.
   PubMed Web of Science ®Google Scholar
• Wibowo AS, Singh M, Reeder KM, et al. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(38):15180–8.
   Google Scholar
• Woodman C, Vundu G, George A, et al. (2021). Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Semin Cancer Biol 69:349–64.
   PubMed Web of Science ®Google Scholar
• Xenaki KT, Oliveira S, van Bergen En Henegouwen PMP. (2017). Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors. Front. Immunol 8:1287.
   PubMed Web of Science ®Google Scholar
• Yuan M, Huang LL, Chen JH, et al. (2019). The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther 4:61.
   PubMed Web of Science ®Google Scholar